James Krueger

James G. Krueger is Head of the Laboratory for Investigative Dermatology at The Rockefeller University in New York, NY, USA. He also serves as Physician and Co-director of the Center for Clinical and Translational Science at the Rockefeller University Hospital, and as Chief Executive Officer of the Rockefeller University Hospital.

Dr Krueger earned his Bachelor's degree from Princeton University (Princeton, NJ, USA) and a PhD degree in virology and cell biology from The Rockefeller University. He received his medical degree from Cornell University Medical College (New York City), where he also completed an internship in internal medicine and a residency in dermatology. Dr Krueger is certified by the American Board of Dermatology.

His research group at The Rockefeller University was the first to conduct clinical trials with specific, targeted immune antagonists in psoriasis and this work established that elimination of pathogenic Tcells from skin lesions could reverse the full pathological phenotype of psoriasis. Since then, his group has used immune-based therapeutics to dissect inflammatory pathways in psoriasis, Hidradenitis suppurativa (HS), and Atopic dermatitis (AD) as well as other inflammatory skin conditions, and to conduct parallel pharmacogenomic studies that define mechanisms of targeted therapeutics in human populations. Dr Krueger has been an advocate of bidirectional translational research (bench to bedside and back) in humans to dissect pathogenic pathways that cannot be studied in animal models, particularly for skin diseases.

Here's a condensed version under 250 words:

Emma Guttman-Yassky, MD, PhD, is the Waldman Professor of Dermatology and Immunology and Health System Chair of the Department of Dermatology at the Icahn School of Medicine at Mount Sinai, New York. She is Director of the Center of Excellence in Eczema, Director of the Laboratory for Inflammatory Skin Diseases, and Co-Director of the Mount Sinai Clinique Skin Aging Center.

Dr. Guttman earned her MD from the Sackler School of Medicine at Tel Aviv University and her PhD from Bar-Ilan University, Israel. After completing dermatology training in Israel, she pursued a postdoctoral fellowship at The Rockefeller University, followed by a second dermatology residency at Weill Cornell Medical College, where she obtained American board certification.

Her research focuses on atopic dermatitis (eczema), hair loss disorders, and skin aging. She has made paradigm-shifting discoveries defining the immunologic basis of atopic dermatitis in both adults and children, leading to the development of targeted therapies. Her work has also advanced the understanding and treatment of alopecia areata, scarring alopecia, chronic hand eczema, keloids, ichthyosis, and other inflammatory skin diseases.

Dr. Guttman co-founded the International Eczema Council and is its past president. She has received numerous national and international awards, delivered keynote and plenary lectures worldwide, and authored more than 475 peer-reviewed publications in leading medical journals.

James G. Krueger is Head of the Laboratory for Investigative Dermatology at The Rockefeller University in New York, NY, USA. He also serves as Physician and Co-director of the Center for Clinical and Translational Science at the Rockefeller University Hospital, and as Chief Executive Officer of the Rockefeller University Hospital.

Dr Krueger earned his Bachelor's degree from Princeton University (Princeton, NJ, USA) and a PhD degree in virology and cell biology from The Rockefeller University. He received his medical degree from Cornell University Medical College (New York City), where he also completed an internship in internal medicine and a residency in dermatology. Dr Krueger is certified by the American Board of Dermatology.

His research group at The Rockefeller University was the first to conduct clinical trials with specific, targeted immune antagonists in psoriasis and this work established that elimination of pathogenic Tcells from skin lesions could reverse the full pathological phenotype of psoriasis. Since then, his group has used immune-based therapeutics to dissect inflammatory pathways in psoriasis, Hidradenitis suppurativa (HS), and Atopic dermatitis (AD) as well as other inflammatory skin conditions, and to conduct parallel pharmacogenomic studies that define mechanisms of targeted therapeutics in human populations. Dr Krueger has been an advocate of bidirectional translational research (bench to bedside and back) in humans to dissect pathogenic pathways that cannot be studied in animal models, particularly for skin diseases.